Payment overview · 2025
General Payments
$2,081.56
127 reported records · 20 companies
Healthcare provider profile · identity verified
James N Spychalski, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · PARKERSBURG, WV · NPI 1689630741
Verified facts
What the public records show
CMS Open Payments records show James N Spychalski, M.D. received $2,081.56 in general payments during 2025 across 127 reported records.
ABBVIE INC. accounted for 22.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 32 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Eliquis, Jardiance, Linzess, Mounjaro, Ozempic, Synthroid, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 123 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 123 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 118 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 178 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $462.98 | 22.2% | 33 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $361.86 | 17.4% | 19 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $195.74 | 9.4% | 16 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $193.65 | 9.3% | 10 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $144.85 | 7.0% | 10 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $141.80 | 6.8% | 9 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $91.63 | 4.4% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $70.83 | 3.4% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $63.48 | 3.0% | 4 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $57.54 | 2.8% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $54.47 | 2.6% | 3 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $47.42 | 2.3% | 2 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $40.81 | 2.0% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $35.22 | 1.7% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $33.26 | 1.6% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $21.43 | 1.0% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $17.94 | 0.9% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $16.66 | 0.8% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $16.00 | 0.8% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.99 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,081.56 | 127 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $217.33 | 11 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $195.83 | 9 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $195.54 | 16 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $161.34 | 10 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $152.71 | 13 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $141.80 | 9 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $135.75 | 9 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $131.69 | 8 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $127.30 | 8 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $127.30 | 8 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $103.19 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $99.34 | 6 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $94.71 | 6 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $91.63 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $70.83 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $63.48 | 4 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $57.54 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $54.47 | 3 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $47.42 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $43.03 | 3 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $40.81 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $35.22 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $33.26 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $21.43 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $21.09 | 2 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $17.94 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $16.66 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $16.23 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $16.00 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $16.00 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $13.99 | 1 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $10.74 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 178 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 123 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 34 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 78 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 118 | exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 46 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
34 | 12 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
46 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
123 | 31 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
63 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
123 | 31 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
78 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
42 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
118 | 27 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
178 | 44 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 634 | 162 |
| Pantoprazole Sodium | Pantoprazole Sodium | 548 | 168 |
| Amlodipine Besylate | Amlodipine Besylate | 529 | 159 |
| Levothyroxine Sodium | Levothyroxine Sodium | 504 | 120 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 390 | 118 |
| Potassium Chloride | Potassium Chloride | 389 | 120 |
| Metoprolol Succinate | Metoprolol Succinate | 288 | 90 |
| Alprazolam | Alprazolam | 284 | 60 |
| Furosemide | Furosemide | 277 | 87 |
| Montelukast Sodium | Montelukast Sodium | 270 | 84 |
| Gabapentin | Gabapentin | 268 | 66 |
| Losartan Potassium | Losartan Potassium | 251 | 65 |
| Omeprazole | Omeprazole | 232 | 62 |
| Clopidogrel | Clopidogrel Bisulfate | 226 | 63 |
| Trazodone Hcl | Trazodone Hcl | 187 | 55 |
| Eliquis | Apixaban | 178 | 44 |
| Metformin Hcl | Metformin Hcl | 168 | 47 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 168 | 52 |
| Sertraline Hcl | Sertraline Hcl | 168 | 39 |
| Lisinopril | Lisinopril | 162 | 48 |
| Metoprolol Tartrate | Metoprolol Tartrate | 159 | 56 |
| Tamsulosin Hcl | Tamsulosin Hcl | 153 | 44 |
| Atenolol | Atenolol | 151 | 41 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 151 | 45 |
| Prednisone | Prednisone | 146 | 65 |
| Escitalopram Oxalate | Escitalopram Oxalate | 143 | 44 |
| Fluoxetine Hcl | Fluoxetine Hcl | 142 | 46 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 142 | 37 |
| Meloxicam | Meloxicam | 137 | 41 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 131 | 38 |
| Azithromycin | Azithromycin | 130 | 104 |
| Jardiance | Empagliflozin | 123 | 31 |
| Ozempic | Semaglutide | 118 | 27 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 116 | 88 |
| Hydrochlorothiazide | Hydrochlorothiazide | 116 | 32 |
| Lorazepam | Lorazepam | 116 | 32 |
| Cefdinir | Cefdinir | 115 | 92 |
| Donepezil Hcl | Donepezil Hcl | 114 | 28 |
| Pioglitazone Hcl | Pioglitazone Hcl | 109 | 32 |
| Doxycycline Hyclate | Doxycycline Hyclate | 108 | 88 |
| Allopurinol | Allopurinol | 107 | 33 |
| Carvedilol | Carvedilol | 107 | 30 |
| Tramadol Hcl | Tramadol Hcl | 104 | 25 |
| Celecoxib | Celecoxib | 102 | 31 |
| Zolpidem Tartrate | Zolpidem Tartrate | 102 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 100 | 26 |
| Ibandronate Sodium | Ibandronate Sodium | 97 | 32 |
| Famotidine | Famotidine | 95 | 31 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 91 | 32 |
| Finasteride | Finasteride | 87 | 24 |
| Metformin Hcl Er | Metformin Hcl | 87 | 28 |
| Quetiapine Fumarate | Quetiapine Fumarate | 87 | 25 |
| Spironolactone | Spironolactone | 87 | 23 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 85 | 26 |
| Glimepiride | Glimepiride | 79 | 20 |
| Mounjaro | Tirzepatide | 78 | 19 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 77 | 24 |
| Simvastatin | Simvastatin | 77 | 21 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 76 | 25 |
| Methocarbamol | Methocarbamol | 75 | 21 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 73 | 18 |
| Metoclopramide Hcl | Metoclopramide Hcl | 72 | 36 |
| Ondansetron Odt | Ondansetron | 70 | 31 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 68 | 15 |
| Bupropion Xl | Bupropion Hcl | 67 | 19 |
| Clonazepam | Clonazepam | 67 | suppressed |
| Fluconazole | Fluconazole | 66 | 46 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 65 | 17 |
| Doxazosin Mesylate | Doxazosin Mesylate | 63 | 25 |
| Xarelto | Rivaroxaban | 63 | 18 |
| Mirtazapine | Mirtazapine | 62 | 18 |
| Ibuprofen | Ibuprofen | 59 | 21 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 58 | 13 |
| Diazepam | Diazepam | 57 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 56 | 35 |
| Cephalexin | Cephalexin | 55 | 36 |
| Buspirone Hcl | Buspirone Hcl | 54 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 54 | 20 |
| Olanzapine | Olanzapine | 54 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 54 | 11 |
| Pregabalin | Pregabalin | 51 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 49 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 49 | 13 |
| Tradjenta | Linagliptin | 49 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 48 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 47 | 14 |
| Synthroid | Levothyroxine Sodium | 46 | 11 |
| Baclofen | Baclofen | 44 | suppressed |
| Levofloxacin | Levofloxacin | 44 | 32 |
| Entresto | Sacubitril/Valsartan | 42 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 42 | 15 |
| Tresiba Flextouch U-200 | Insulin Degludec | 42 | suppressed |
| Amoxicillin | Amoxicillin | 40 | 26 |
| Memantine Hcl | Memantine Hcl | 40 | 11 |
| Levetiracetam | Levetiracetam | 39 | suppressed |
| Sucralfate | Sucralfate | 39 | 17 |
| Farxiga | Dapagliflozin Propanediol | 38 | suppressed |
| Loperamide | Loperamide Hcl | 38 | 13 |
| Estradiol | Estradiol | 37 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 37 | 14 |
| Meclizine Hcl | Meclizine Hcl | 37 | 18 |
| Trulicity | Dulaglutide | 37 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 36 | suppressed |
| Methotrexate | Methotrexate Sodium | 36 | 11 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 35 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 35 | 12 |
| Warfarin Sodium | Warfarin Sodium | 35 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 34 | 30 |
| Diltiazem 12hr Er | Diltiazem Hcl | 34 | 11 |
| Ezetimibe | Ezetimibe | 34 | 11 |
| Linzess | Linaclotide | 34 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 34 | 15 |
| Temazepam | Temazepam | 33 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 33 | suppressed |
| Lactulose | Lactulose | 32 | 11 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 32 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 32 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | 12 |
| Bupropion Hcl Sr | Bupropion Hcl | 30 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 30 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 30 | 11 |
| Myrbetriq | Mirabegron | 30 | suppressed |
| Nystatin | Nystatin | 30 | 19 |
| Amiodarone Hcl | Amiodarone Hcl | 29 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 29 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 29 | suppressed |
| Topiramate | Topiramate | 29 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 28 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 28 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 28 | suppressed |
| Verapamil Er | Verapamil Hcl | 28 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 27 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 27 | 11 |
| Memantine Hcl Er | Memantine Hcl | 27 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 26 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 25 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 24 | suppressed |
| Verapamil Sr | Verapamil Hcl | 24 | suppressed |
| Eszopiclone | Eszopiclone | 23 | suppressed |
| Metronidazole | Metronidazole | 23 | 18 |
| Ranolazine Er | Ranolazine | 23 | suppressed |
| Aripiprazole | Aripiprazole | 22 | suppressed |
| Bumetanide | Bumetanide | 22 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 22 | suppressed |
| Ketoconazole | Ketoconazole | 22 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 21 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 21 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 21 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Lamotrigine | Lamotrigine | 20 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 20 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Creon | Lipase/Protease/Amylase | 19 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 19 | suppressed |
| Nabumetone | Nabumetone | 19 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 19 | 14 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 18 | suppressed |
| Irbesartan | Irbesartan | 18 | suppressed |
| Hydrocortisone | Hydrocortisone | 17 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 17 | suppressed |
| Klor-Con M20 | Potassium Chloride | 17 | 11 |
| Latanoprost | Latanoprost | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Clotrimazole | Clotrimazole | 16 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 16 | suppressed |
| Sulindac | Sulindac | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | 11 |
| Nortriptyline Hcl | Nortriptyline Hcl | 15 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Dexamethasone | Dexamethasone | 13 | 13 |
| Fentanyl | Fentanyl | 13 | suppressed |
| Klor-Con M10 | Potassium Chloride | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Pioglitazone-Metformin | Pioglitazone Hcl/Metformin Hcl | 13 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Diclofenac Sodium-Misoprostol | Diclofenac Sodium/Misoprostol | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Enulose | Lactulose | 12 | suppressed |
| Linezolid | Linezolid | 12 | 11 |
| Methylphenidate Hcl | Methylphenidate Hcl | 12 | suppressed |
| Modafinil | Modafinil | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Penicillin V Potassium | Penicillin V Potassium | 12 | 12 |
| Lovastatin | Lovastatin | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,081.56 · 127 records | ABBVIE INC. | AIRSUPRA, BREZTRI, CAPLYTA, CAPVAXIVE, CREON, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, GARDASIL 9, JARDIANCE, Kerendia, Korlym, LEQVIO, LINZESS, MOUNJARO, NURTEC ODT, Ohtuvayre, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, SPRAVATO, SYNTHROID, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, VRAYLAR, Wegovy, YUPELRI, ZAVZPRET, ZEPBOUND | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error